- Home
- RRR vs LNTH Comparison
RRR vs LNTH Comparison
Compare RRR & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- LNTH
- Stock Information
- Founded
- RRR 1976
- LNTH 1956
- Country
- RRR United States
- LNTH United States
- Employees
- RRR N/A
- LNTH N/A
- Industry
- RRR Hotels/Resorts
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RRR Consumer Discretionary
- LNTH Health Care
- Exchange
- RRR Nasdaq
- LNTH Nasdaq
- Market Cap
- RRR 3.5B
- LNTH 3.8B
- IPO Year
- RRR 2016
- LNTH 2015
- Fundamental
- Price
- RRR $58.75
- LNTH $53.33
- Analyst Decision
- RRR Buy
- LNTH Buy
- Analyst Count
- RRR 13
- LNTH 6
- Target Price
- RRR $61.54
- LNTH $74.17
- AVG Volume (30 Days)
- RRR 850.6K
- LNTH 1.3M
- Earning Date
- RRR 10-28-2025
- LNTH 11-06-2025
- Dividend Yield
- RRR 3.47%
- LNTH N/A
- EPS Growth
- RRR 15.51
- LNTH N/A
- EPS
- RRR 3.14
- LNTH 2.39
- Revenue
- RRR $1,995,401,000.00
- LNTH $1,525,933,000.00
- Revenue This Year
- RRR $4.18
- LNTH N/A
- Revenue Next Year
- RRR $3.27
- LNTH $1.98
- P/E Ratio
- RRR $18.72
- LNTH $22.30
- Revenue Growth
- RRR 4.69
- LNTH 1.95
- 52 Week Low
- RRR $35.09
- LNTH $47.25
- 52 Week High
- RRR $63.60
- LNTH $111.29
- Technical
- Relative Strength Index (RSI)
- RRR 54.71
- LNTH 44.67
- Support Level
- RRR $53.35
- LNTH $50.16
- Resistance Level
- RRR $60.16
- LNTH $61.92
- Average True Range (ATR)
- RRR 1.89
- LNTH 2.49
- MACD
- RRR 0.35
- LNTH -0.61
- Stochastic Oscillator
- RRR 68.70
- LNTH 26.56
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.